H.C. Wainwright raised the firm’s price target on Equillium to $5 from $4 and keeps a Buy rating on the shares. The analyst says the EQUALISE Part B top-line data remains positive, maintaining a favorable outlook for the company’s Ono Pharmaceutical option exercise.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
